Increased total homocysteine levels predict the risk of incident dementia independent of cerebral small-vessel diseases and vascular risk factors

Journal of Alzheimer's Disease

Volumn 49, Issue 2, 2015, Pages 503-513

  Miwa, Kaori ^a   Tanaka, Makiko ^b   Okazaki, Shuhei ^a   Yagita, Yoshiki ^c   Sakaguchi, Manabu ^a   Mochizuki, Hideki ^a   Kitagawa, Kazuo ^d  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOSHIGAOKA KOSEINENKIN HOSPITAL   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; cerebral small vessel disease; dementia; estimated glomerular filtration rate; homocysteine; microbleeds; vascular dementia

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTERIAL WALL THICKNESS; ARTICLE; BRAIN ATROPHY; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; DEMENTIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; WHITE MATTER; BLOOD; CEREBRAL SMALL VESSEL DISEASES; INCIDENCE; LONGITUDINAL STUDY; MENTAL HEALTH; MIDDLE AGED; MORTALITY; NEUROPSYCHOLOGICAL TEST; NONPARAMETRIC TEST; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL;

AGED; CAROTID INTIMA-MEDIA THICKNESS; CEREBRAL SMALL VESSEL DISEASES; DEMENTIA; FEMALE; HOMOCYSTEINE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 84948689005     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150458     Document Type: Article

References (46)

1. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I (1991) Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 324, 1149-1155.
2. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke:Ameta-Analysis. JAMA 288, 2015-2022.
3. Hassan A, Hunt BJ, O'SullivanM, Bell R, D'Souza R, Jeffery S, Bamford JM, Markus HS (2004) Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 127, 212-219.
4. Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S (2011) Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42, 2672-2713.
5. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346, 476-483.
6. Zylberstein DE, Lissner L, Bjorkelund C, Mehlig K, Thelle DS, Gustafson D, Ostling S, Waern M, Guo X, Skoog I (2011) Midlife homocysteine and late-life dementia in women. A prospective population study. Neurobiol Aging 32, 380-386.
7. Ford AH, Flicker L, Alfonso H, Hankey GJ, Norman PE, van Bockxmeer FM, Almeida OP (2012) Plasma homocysteine and MTHFRC677T polymorphism as risk factors for incident dementia. J Neurol Neurosurg Psychiatry 83, 70-75.
8. Hooshmand B, Solomon A, Kareholt I, Leiviska J, Rusanen M, Ahtiluoto S, Winblad B, Laatikainen T, Soininen H, Kivipelto M (2010) Homocysteine and holotranscobalamin and the risk of Alzheimer disease: A longitudinal study. Neurology 75, 1408-1414.
9. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R (2004) Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62, 1972-1976.
10. Ariogul S, Cankurtaran M, Dagli N, Khalil M, YavuzB(2005) Vitamin B12, folate, homocysteine and dementia: Are they really related? Arch Gerontol Geriatr 40, 139-146.
11. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201.
12. Kalaria RN (2012) Cerebrovascular disease and mechanisms of cognitive impairment: Evidence from clinicopathological studies in humans. Stroke 43, 2526-2534.
13. Miwa K, Tanaka M, Okazaki S, Furukado S, Yagita Y, Sakaguchi M, Mochizuki H, Kitagawa K (2014) Chronic kidney disease is associated with dementia independent of cerebral small-vessel disease. Neurology 82, 1051-1057.
14. Miwa K, Tanaka M, Okazaki S, Yagita Y, Sakaguchi M, Mochizuki H, Kitagawa K (2014) Multiple or mixed cerebral microbleeds and dementia in patients with vascular risk factors. Neurology 83, 646-653.
15. Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T, Nigwekar SU, GallagherMP, Cass A, Strippoli G, Perkovic V (2012) The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: Systematic review and meta-Analysis. BMJ 344, e3533.
16. Miwa K, Tanaka M, Okazaki S, Furukado S, Sakaguchi M, Mochizuki H, Kitagawa K (2013) Association between interleukin-6 levels and first-ever cerebrovascular events in patients with vascular risk factors. Arterioscler Thromb Vasc Biol 33, 400-405.
17. Miwa K, Tanaka M, Okazaki S, Furukado S, Sakaguchi M, Kitagawa K (2011) Relations of blood inflammatory marker levels with cerebral microbleeds. Stroke 42, 3202-3206.
18. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
19. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140, 566-572.
20. Pantoni L (2010) Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9, 689-701.
21. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, Steinling M, Valk J (1993) A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 114, 7-12.
22. Ishii H, Meguro K, Yamaguchi S, Hirayama K, Tabuchi M, Mori E, Yamadori A (2006) Different MRI findings for normal elderly and very mild Alzheimer's disease in a community: Implications for clinical practice the Tajiri Project. Arch Gerontol Geriatr 42, 59-71.
23. Brickman AM, Honig LS, Scarmeas N, Tatarina O, Sanders L, Albert MS, Brandt J, Blacker D, Stern Y (2008) Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol 65, 1202-1208.
24. Guidelines for the Management of Hypertension 2004. Japanese Society of Hypertension.
25. International Expert, Committee (2009) International Expert Committee report on the role of theA1Cassay in the diagnosis of diabetes. Diabetes Care 32, 1327-1334.
26. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M (2007) Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14, 155-158.
27. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53, 982-992.
28. Yamagami H, Kitagawa K, Hoshi T, Furukado S, Hougaku H, Nagai Y, Hori M (2005) Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol 25, 1458-1462.
29. Hoshi T, Yamagami H, Furukado S, Miwa K, Tanaka M, Sakaguchi M, Sakoda S, Kitagawa K (2010) Serum inflammatory proteins and frontal lobe dysfunction in patients with cardiovascular risk factors. Eur J Neurol 17, 1134-1140.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (2010) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
31. Roman GC, Tatemichi TK, Erkinjuntti T (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
32. Bombois S, Debette S, Bruandet A, Delbeuck X, Delmaire C, Leys D, Pasquier F (2008) Vascular subcortical hyperintensities predict conversion to vascular and mixed dementia in MCI patients. Stroke 39, 2046-2051.
33. Nygard O, Refsum H, Ueland PM, Vollset SE (1998) Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study. Am J Clin Nutr 67, 263-270.
34. Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, Kitajima S (2001) Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 276, 35867-35874.
35. Durand P, Lussier-Cacan S, Blache D (1997) Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophagederived tissue factor activity in rats. FASEB J 11, 1157-1168.
36. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J (1993) Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91, 308-318.
37. Marti-Carvajal AJ, Sola I, Lathyris D, Karakitsiou DE, Simancas-Racines D (2013) Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 1, CD006612.
38. The VITATOPS, Trial Study Group (2010) B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: A randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 9, 855-865.
39. Kloppenborg RP, Geerlings MI, Visseren FL, Mali WP, Vermeulen M, van der Graaf Y, Nederkoorn PJ (2014) Homocysteine and progression of generalized small-vessel disease: The SMART-MR Study. Neurology 82, 777-783.
40. den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, Breteler MM (2003) Homocysteine and brain atrophy onMRI of non-demented elderly. Brain 126, 170-175.
41. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM(1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55, 1449-1455.
42. Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Myllykangas L, Erkinjuntti T, Makela M, Oinas M, Paetau A, Scheltens P, van Straaten EC, Sulkava R, Solomon A (2013) Plasma homocysteine, Alzheimer and cerebrovascular pathology: A population-based autopsy study. Brain 136, 2707-2716.
43. Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, Jacques PF, Yoshita M, Rosenberg IH, D'Agostino RB, DeCarli C (2008) Association of plasma total homocysteine levels with subclinical brain injury: Cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 65, 642-649.
44. Li JG, Chu J, Barrero C, Merali S, Pratico D (2014) Homocysteine exacerbates beta-Amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann Neurol 75, 851-863.
45. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-Analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat Genet 39, 17-23.
46. ClarkeR, Bennett D, Parish S, Lewington S, SkeaffM, Eussen SJ, Lewerin C, Stott DJ, Armitage J, Hankey GJ, Lonn E, Spence JD, Galan P, de Groot LC, Halsey J, Dangour AD, Collins R, Grodstein F (2014) Effects of homocysteine lowering with B vitamins on cognitive aging: Meta-Analysis of 11 trials with cognitive data on 22, 000 individuals. Am J Clin Nutr 100, 657-666.